China Universal CNI BIOMEDICINE ETF (159839) rises 2.79%, with the latest margin financing purchase amount reaching 6.7191 million yuan

NewTimeSpace (newtimespace.com) News, as of 14:13 on July 15, 2026, China Universal Biopharmaceutical ETF (159839) rose 2.79%, with the latest price at 0.37 yuan. Over a longer time frame, as of July 14, 2026, the ETF accumulated a gain of 6.23% over the past week.

In terms of liquidity, China Universal Biopharmaceutical ETF recorded an intraday turnover rate of 12.05% and a trading volume of 142 million yuan, indicating active market trading. Over a longer time frame, as of July 14, the ETF's average daily trading volume over the past month reached 73.6439 million yuan.

In terms of scale, the latest scale of China Universal Biopharmaceutical ETF reached 1.131 billion yuan, hitting a one-year high. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of China Universal Biopharmaceutical ETF reached 6.7191 million yuan, with the latest margin financing balance standing at 75.6818 million yuan. (Data source: Wind)

As of July 14, the net value of China Universal Biopharmaceutical ETF rose by 12.73% over the past two years. From the perspective of return capability, as of July 14, 2026, since its inception, the ETF achieved a highest single-month return of 27.69%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 31.17%, and an average return of 5.65% in up months. As of July 14, 2026, the ETF's annualized excess return over its benchmark for the past three months was 2.81%.

In terms of drawdown, as of July 14, 2026, China Universal Biopharmaceutical ETF recorded a drawdown of 0.20% relative to its benchmark over the past six months.

In terms of fees, China Universal Biopharmaceutical ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of July 14, 2026, the five-year tracking error of China Universal Biopharmaceutical ETF was 0.029%, achieving the highest tracking accuracy among comparable funds.

China Universal Biopharmaceutical ETF closely tracks the Guosen Biopharmaceutical Index. The Guosen Biopharmaceutical Index takes listed companies related to the biopharmaceutical industry on the Shanghai, Shenzhen, and Beijing stock exchanges as the sample space. Based on a comprehensive ranking of market capitalization and liquidity, it selects the top 30 securities as index constituents. It reflects the overall operation of the biopharmaceutical industry and provides market participants with index-based investment targets for the sub-industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.